{"organizations": [], "uuid": "aae9b9aa5c501c8a215b500073c385bb52484d73", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-corcept-therapeutics-receives-lett/brief-corcept-therapeutics-receives-letter-on-saying-teva-pharmaceuticals-usa-submitted-an-abbreviated-new-drug-application-idUSFWN1PV0X2", "country": "US", "domain_rank": 408, "title": "BRIEF-Corcept Therapeutics Receives Letter on saying Teva Pharmaceuticals USA Submitted An Abbreviated New Drug Application", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-05T15:50:00.000+02:00", "replies_count": 0, "uuid": "aae9b9aa5c501c8a215b500073c385bb52484d73"}, "author": "", "url": "https://www.reuters.com/article/brief-corcept-therapeutics-receives-lett/brief-corcept-therapeutics-receives-letter-on-saying-teva-pharmaceuticals-usa-submitted-an-abbreviated-new-drug-application-idUSFWN1PV0X2", "ord_in_thread": 0, "title": "BRIEF-Corcept Therapeutics Receives Letter on saying Teva Pharmaceuticals USA Submitted An Abbreviated New Drug Application", "locations": [], "entities": {"persons": [], "locations": [{"name": "usa", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "teva pharmaceuticals usa", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}, {"name": "fda", "sentiment": "none"}, {"name": "pharmaceuticals usa submitted an abbreviated new drug application reuters", "sentiment": "none"}, {"name": "teva pharma usa", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "teva", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "corcept therapeutics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 5, 2018 / 1:52 PM / in 15 minutes BRIEF-Corcept Therapeutics Receives Letter on saying Teva Pharmaceuticals USA Submitted An Abbreviated New Drug Application Reuters Staff 1 Min Read \nFeb 5 (Reuters) - Corcept Therapeutics Inc: \n* CORCEPT THERAPEUTICS - RECEIVED PARAGRAPH IV NOTICE LETTER ADVISING THAT TEVA PHARMACEUTICALS USA SUBMITTED AN ABBREVIATED NEW DRUG APPLICATION TO FDA \n* CORCEPT THERAPEUTICS - TEVA PHARMA USA SUBMITTED ANDA SEEKING AUTHORIZATION TO MANUFACTURE, USE, SELL GENERIC VERSION OF KORLYM MIFEPRISTONE TABLETS IN U.S. \n* CORCEPT THERAPEUTICS SAYS NOTICE LETTER ALLEGES THAT KORLYM PATENTS WILL NOT BE INFRINGED BY TEVAâ€˜S PROPOSED PRODUCT - SEC FILING Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-05T15:50:00.000+02:00", "crawled": "2018-02-05T16:12:49.022+02:00", "highlightTitle": ""}